Cargando…

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling...

Descripción completa

Detalles Bibliográficos
Autores principales: Herdman, M., Gudex, C., Lloyd, A., Janssen, MF., Kind, P., Parkin, D., Bonsel, G., Badia, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220807/
https://www.ncbi.nlm.nih.gov/pubmed/21479777
http://dx.doi.org/10.1007/s11136-011-9903-x
_version_ 1782216998071042048
author Herdman, M.
Gudex, C.
Lloyd, A.
Janssen, MF.
Kind, P.
Parkin, D.
Bonsel, G.
Badia, X.
author_facet Herdman, M.
Gudex, C.
Lloyd, A.
Janssen, MF.
Kind, P.
Parkin, D.
Bonsel, G.
Badia, X.
author_sort Herdman, M.
collection PubMed
description PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects.
format Online
Article
Text
id pubmed-3220807
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-32208072011-12-09 Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Herdman, M. Gudex, C. Lloyd, A. Janssen, MF. Kind, P. Parkin, D. Bonsel, G. Badia, X. Qual Life Res Article PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects. Springer Netherlands 2011-04-09 2011 /pmc/articles/PMC3220807/ /pubmed/21479777 http://dx.doi.org/10.1007/s11136-011-9903-x Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Herdman, M.
Gudex, C.
Lloyd, A.
Janssen, MF.
Kind, P.
Parkin, D.
Bonsel, G.
Badia, X.
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title_full Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title_fullStr Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title_full_unstemmed Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title_short Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
title_sort development and preliminary testing of the new five-level version of eq-5d (eq-5d-5l)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220807/
https://www.ncbi.nlm.nih.gov/pubmed/21479777
http://dx.doi.org/10.1007/s11136-011-9903-x
work_keys_str_mv AT herdmanm developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT gudexc developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT lloyda developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT janssenmf developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT kindp developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT parkind developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT bonselg developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l
AT badiax developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l